POR and prostate carcinoma: Specific inhibition of CYP17A1 lyase activity and not hydroxylase activity, that is relevant in the treatment of prostate cancer and polycystic ovary syndrome59, may thus be achieved by targeting POR as an alternative to targeting CYP17A1 directly.